Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 120 participants.

Also called NCT04702490

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Metacrine, Inc. (from the registry)
Registry
  • NCT NCT04702490
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04702490. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-15 (actual); primary completion 2022-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
Condition
NASH
Condition
NASH - Nonalcoholic Steatohepatitis
Condition
Diabetes Type 2
Condition
Diabetes
Condition
Fatty Liver
Condition
Fatty Liver, Nonalcoholic
Condition
NAFLD
Intervention (Drug)
MET409 Active
Intervention (Drug)
MET409 Placebo
Intervention (Drug)
Empagliflozin
Lead sponsor
Metacrine, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04702490
Content hash
483a54afb3568f23f5998c06d800df1017e8faf7de6fc47092091cf2ae897936